I don't pretend to be an SDIX expert, but looking at the flat revenue, the lack of profits and the exuberant reaction of the stock price upon receiving FDA buy off on a single test, I can understand the thought process that might lead you to believe what is good for SDIX is bad for NEOG.
NEOG, however, is hardly a one trick pony. That one test is not going to be a huge determinant in the share price, even if one were to concede the entire market to SDIX, which I don't think will happen.
NEOG is down because it had a very strong run in the last year that was, frankly, a bit exaggerated. Shorts pulled out and are undoubtedly starting to come back. Profits are being taken. I also suspect some people were, unrealistically, expecting the food safety bill to magically turn into an immediate revenue bump and moved on to some other "get rich quick" scheme.
In the meantime, even with the recent price decline, we've had a very good return in the last 12 months and I think the next 12 months will be very good, as well.